HUTCHMED DRC
$ 15.08
-0.59%
24 Feb - close price
- Market Cap 2,739,724,000 USD
- Current Price $ 15.08
- High / Low $ 15.17 / 14.79
- Stock P/E 5.72
- Book Value 1.43
- EPS 2.65
- Next Earning Report 2026-03-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.01 %
- ROE 0.47 %
- 52 Week High 19.50
- 52 Week Low 11.51
About
HUTCHMED (China) Limited discovers, develops and markets targeted immunotherapies and therapies for cancer and immune diseases globally. The company is headquartered in Central, Hong Kong.
Analyst Target Price
$21.11
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-28 | 2025-08-07 | 2025-05-28 | 2025-03-19 | 2024-11-29 | 2024-07-31 | 2024-05-29 | 2024-02-28 | 2023-11-10 | 2023-07-31 | 2023-05-31 | 2023-02-28 |
| Reported EPS | 0 | 0.52 | 0 | 0.01 | 0 | 0 | 0 | -0.7 | 0 | 0.97 | 0 | -1.02 |
| Estimated EPS | 0 | 0 | 0 | 0.04 | 0 | 0 | 0 | -1.08 | 0.04 | -0.055 | -0.05 | -1.02 |
| Surprise | 0 | 0.52 | 0 | -0.03 | 0 | 0 | 0 | 0.38 | -0.04 | 1.025 | 0.05 | 0 |
| Surprise Percentage | None% | None% | None% | -75% | None% | None% | None% | 35.1852% | -100% | 1863.6364% | 100% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-05 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HCM
2026-02-06 14:29:14
HUTCHMED (China) Limited announced it will release its 2025 final results on Thursday, March 5, 2026. The company will host two webcast presentations for analysts and investors to discuss the results, with sessions in English and Chinese (Putonghua). These webcasts will be accessible live on the company's website, with replays also available.
2026-02-06 12:57:53
HUTCHMED (China) Limited will announce its final results for the year ending December 31, 2025, on March 5, 2026, at 6:00 am EST. Following the announcement, two webcasts will be held for analysts and investors: an English webcast on March 5th at 8:00 am EST and a Chinese webcast on March 6th at 8:30 am HKT. The company, a biopharmaceutical firm, focuses on developing and commercializing therapies for cancer and immunological diseases.
2026-02-06 10:30:19
HUTCHMED will release its final results for the year ended December 31, 2025, on March 5, 2026, at 6:00 am EST. Management will host two webcasts on the same day for analysts and investors, with an English webcast at 8:00 am EST and a Chinese webcast on March 6 at 8:30 am HKT. The company is a commercial-stage biopharmaceutical firm focused on targeted therapies and immunotherapies for cancer and immunological diseases.
2026-02-06 08:30:19
HUTCHMED (China) Limited will announce its final results for the year ended December 31, 2025, on Thursday, March 5, 2026. Management will host two webcast presentations (English and Chinese) for analysts and investors to discuss the results and hold Q&A sessions. The webcasts will be available live on the company's website, with replay options provided shortly after the event.
2026-02-06 08:30:19
HUTCHMED (China) Limited will release its financial results for the year ended December 31, 2025, on Thursday, March 5, 2026, at 6:00 am Eastern Standard Time. Following the announcement, the company will host two webcasts for analysts and investors: an English presentation on March 5 at 8:00 am EST and a Chinese session on March 6 at 8:30 am HKT. HUTCHMED is a biopharmaceutical company focusing on cancer and immunological diseases, with three medicines marketed in China and one approved internationally.
2026-02-06 08:30:19
HUTCHMED (China) Limited will announce its final results for the year ending December 31, 2025, on March 5, 2026, at 6:00 am EST. The company will host two webcast presentations for analysts and investors, one in English and one in Chinese, to discuss the results and conduct Q&A sessions. HUTCHMED is a biopharmaceutical company focused on developing targeted therapies and immunotherapies for cancer and immunological diseases.
